DE69534874D1 - Immunotherapeutische stress-protein-peptidkomplexe gegen krebs - Google Patents

Immunotherapeutische stress-protein-peptidkomplexe gegen krebs

Info

Publication number
DE69534874D1
DE69534874D1 DE69534874T DE69534874T DE69534874D1 DE 69534874 D1 DE69534874 D1 DE 69534874D1 DE 69534874 T DE69534874 T DE 69534874T DE 69534874 T DE69534874 T DE 69534874T DE 69534874 D1 DE69534874 D1 DE 69534874D1
Authority
DE
Germany
Prior art keywords
peptide
mammal
protein
stress
peptide complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534874T
Other languages
English (en)
Other versions
DE69534874T2 (de
Inventor
K Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Application granted granted Critical
Publication of DE69534874D1 publication Critical patent/DE69534874D1/de
Publication of DE69534874T2 publication Critical patent/DE69534874T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
DE69534874T 1994-09-30 1995-04-06 Immunotherapeutische stress-protein-peptidkomplexe gegen krebs Expired - Lifetime DE69534874T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/315,892 US5750119A (en) 1994-01-13 1994-09-30 Immunotherapeutic stress protein-peptide complexes against cancer
US315892 1994-09-30
PCT/US1995/004347 WO1996010411A1 (en) 1994-09-30 1995-04-06 Immunotherapeutic stress protein-peptide complexes against cancer

Publications (2)

Publication Number Publication Date
DE69534874D1 true DE69534874D1 (de) 2006-05-11
DE69534874T2 DE69534874T2 (de) 2006-12-14

Family

ID=23226518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534874T Expired - Lifetime DE69534874T2 (de) 1994-09-30 1995-04-06 Immunotherapeutische stress-protein-peptidkomplexe gegen krebs

Country Status (13)

Country Link
US (6) US5750119A (de)
EP (2) EP0784477B1 (de)
JP (3) JPH10506628A (de)
KR (1) KR970706013A (de)
CN (1) CN1167440A (de)
AT (1) ATE320447T1 (de)
AU (1) AU709643B2 (de)
CA (1) CA2201498A1 (de)
DE (1) DE69534874T2 (de)
DK (1) DK0784477T3 (de)
ES (1) ES2260762T3 (de)
PT (1) PT784477E (de)
WO (1) WO1996010411A1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6331299B1 (en) * 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
JP4163253B2 (ja) 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質に基づくワクチンおよび免疫療法
US6719974B1 (en) * 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
EP0950061A4 (de) 1996-09-20 2000-04-12 Univ New Mexico Hitzeschockproteinkomplexe
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
NZ511550A (en) * 1997-05-12 2005-03-24 Aphton Corp CCK-B/gastrin receptor inhibitors for the treatment of tumors
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
NZ538399A (en) 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
JP2002501722A (ja) * 1997-10-31 2002-01-22 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質結合性コンジュゲートペプチド
AU1045199A (en) * 1997-11-05 1999-05-24 Isis Innovation Limited Cancer gene
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ES2439014T3 (es) 1998-02-20 2014-01-21 The University Of Miami Complejo de péptido antigénico-proteína de choque térmico modificada
EP1060247B2 (de) * 1998-02-24 2011-10-26 Sisters of Providence in Oregon Ox-40-rezeptor-bindemittel zur verwendung in verfahren zur verbesserung der antigenspezifischen immunantwort gegen tumore
CA2328501A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Prevention and treatment of hypergastrinemia
AU2004200711B2 (en) * 1998-08-19 2005-11-10 Immunobiology Limited Vaccine Comprising Cytokine-Induced Heat Shock Proteins (HSP)
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
US6797480B1 (en) * 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6730302B1 (en) * 1998-11-24 2004-05-04 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kD heat shock protein
WO2001040292A1 (en) * 1998-11-27 2001-06-07 Novopharm Biotech Inc. Antigen-binding fragments specific for tumor associated antigens
US6495360B1 (en) 1999-05-28 2002-12-17 Photogen, Inc. Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins
EP1196772A2 (de) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induktion einer th1-vermittelten immunantwort in vitro
US6984384B1 (en) 1999-09-30 2006-01-10 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
CA2406472A1 (en) * 2000-04-17 2001-10-25 James E. Rothman Javelinization of protein antigens to heat shock proteins
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
DE60119734T2 (de) * 2000-06-26 2007-04-26 Stressgen Biotechnologies Corp., Victoria Hpv-e7 zur behandlung von menschlichem papillomavirus
CA2417214C (en) * 2000-08-03 2016-06-21 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
WO2002011669A2 (en) * 2000-08-07 2002-02-14 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
WO2002032923A2 (en) * 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
MXPA03006971A (es) 2001-02-05 2004-05-05 Stressgen Biotechnologies Corp Tratamiento del virus de hepatitis b.
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
AU2002252456A1 (en) * 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
US6875849B2 (en) * 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
JP4384489B2 (ja) * 2001-08-20 2009-12-16 ユニバーシティー オブ コネティカット ヘルス センター 癌及び感染性疾患の治療に有用な熱ショックタンパク質又はα−２−マクログロブリンを含む組成物の調製方法
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
EP1551957A4 (de) * 2001-10-01 2007-01-24 Univ Duke Isoliertes polypeptid der grp94-ligandenbindungsdomäne und dafür codierende nukleinsäure, kristalline form davon sowie durchmusterungsverfahren, bei dem es verwendet wird
US20040071656A1 (en) * 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
EP1572933A4 (de) * 2002-02-13 2007-09-05 Univ Duke Modulation der immunantwort durch polypeptide als antwort auf nichtpeptidischen bindungsstress
CN1780919A (zh) * 2002-02-28 2006-05-31 抗基因公司 基于应激蛋白寡聚化的方法和产品
RU2376029C2 (ru) 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
AU2003234469A1 (en) * 2002-05-02 2003-11-17 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
AU2003301296A1 (en) * 2002-05-02 2004-05-04 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines
WO2004037321A2 (en) * 2002-10-25 2004-05-06 University Of Connecticut Health Center Immunotherapy of cancer through controlled cell lysis
WO2004055517A2 (en) 2002-12-13 2004-07-01 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7550256B2 (en) 2002-12-13 2009-06-23 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7226748B2 (en) * 2003-01-03 2007-06-05 Aurelium Biopharma, Inc. HSC70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
EP1608384A2 (de) * 2003-01-28 2005-12-28 Shanghai Sunway Biotech Co Ltd Therapie für primären und metastasierenden krebs
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
AU2004213855B2 (en) 2003-02-20 2010-03-04 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
AU2003223226A1 (en) * 2003-02-20 2004-09-17 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
WO2005020936A2 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US7358042B2 (en) * 2003-03-14 2008-04-15 Aurelium Biopharma, Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP1644048B1 (de) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
CA2532035A1 (en) * 2003-07-07 2005-02-03 The General Hospital Corporation Fugetactic proteins, compositions and methods of use
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
JP5576592B2 (ja) * 2004-03-29 2014-08-20 キャンサー アドヴァンシズ インコーポレイテッド ガストリンホルモンに対するモノクローナル抗体
CN101005760A (zh) * 2004-06-04 2007-07-25 塞尔-赛公司 改变cd4/cd8和进入肿瘤的单核细胞浸润液的方法
EP1794586B1 (de) * 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoklonale antikörper gegen progastrin
EP1814981A4 (de) * 2004-10-25 2009-09-30 Baylor Res Inst Mit hitzeschock-behandelten melanomzellkörpern beladene dendritische zellen
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
JP2008528004A (ja) * 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン
US20070202106A1 (en) * 2005-10-06 2007-08-30 Baylor Research Institute Compositions and methods for the treatment of cancer
US20070237763A1 (en) * 2005-10-06 2007-10-11 Baylor Research Institute Compositions and methods for the treatment of cancer
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
ES2460899T3 (es) 2008-03-03 2014-05-14 The University Of Miami Inmunoterapia basada en células cancerosas alógenas
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
CN101297966B (zh) * 2008-06-16 2012-03-21 黄常新 肠癌富伴侣分子-抗原肽复合物瘤苗及其制备方法
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
WO2010115118A2 (en) 2009-04-03 2010-10-07 Antigenics, Inc. Methods for preparing and using multichaperone-antigen complexes
GB0910591D0 (en) * 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
CN103372209B (zh) * 2012-04-24 2014-09-17 中国科学院微生物研究所 gp96蛋白的抗体在制备癌细胞抑制剂中的应用
KR101594403B1 (ko) * 2014-03-11 2016-02-16 연세대학교 산학협력단 HSP 90a 를 포함하는 암 또는 바이러스 질환 치료용 조성물
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
WO2016161309A1 (en) * 2015-04-01 2016-10-06 Colorado State University Research Foundation Optimized cancer stem cell vaccines
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
CN106279393A (zh) * 2016-08-29 2017-01-04 拜西欧斯（北京）生物技术有限公司 一种gp96蛋白纯化方法
WO2018071405A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
CN106963940A (zh) * 2017-04-07 2017-07-21 江苏食品药品职业技术学院 一种增强抗肿瘤免疫应答的复合物
WO2018232230A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
EP0419569B1 (de) * 1988-06-15 1995-09-06 Whitehead Institute For Biomedical Research Stressproteine und verwendungen dafür
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) * 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
DK0556248T3 (da) * 1990-11-08 1997-10-27 Univ London Mycobacterium som adjuvans til antigener
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US5225399A (en) * 1991-04-15 1993-07-06 The Children's Hospital Of Philadelphia Antimicrobial amphiphilic peptides
GB9200949D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
CA2383007A1 (en) * 1992-03-02 1993-09-16 Chiron S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
FR2688227A1 (fr) * 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
HUT70972A (en) * 1992-03-09 1995-11-28 Ist Naz Stud Cura Dei Tumori Protein compound capable of inhibiting tumoral growth
CA2118015A1 (en) * 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1994003599A1 (en) * 1992-08-04 1994-02-17 Sagami Chemical Research Center HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5680984A (en) * 1994-05-13 1997-10-28 Matsushita Electric Industrial Co., Ltd. Apparatus and method for mounting soldering balls onto surfaces of electronic components
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6984384B1 (en) * 1999-09-30 2006-01-10 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease

Also Published As

Publication number Publication date
US20030165519A1 (en) 2003-09-04
CA2201498A1 (en) 1996-04-11
JPH10506628A (ja) 1998-06-30
DK0784477T3 (da) 2006-07-17
AU709643B2 (en) 1999-09-02
ES2260762T3 (es) 2006-11-01
EP0784477B1 (de) 2006-03-15
US20020061316A1 (en) 2002-05-23
US6017544A (en) 2000-01-25
DE69534874T2 (de) 2006-12-14
EP1702624A1 (de) 2006-09-20
US6468540B1 (en) 2002-10-22
EP0784477A1 (de) 1997-07-23
EP0784477A4 (de) 2000-06-14
WO1996010411A1 (en) 1996-04-11
US5750119A (en) 1998-05-12
CN1167440A (zh) 1997-12-10
ATE320447T1 (de) 2006-04-15
JP2005015489A (ja) 2005-01-20
JP2008069167A (ja) 2008-03-27
PT784477E (pt) 2006-08-31
US20050163793A1 (en) 2005-07-28
KR970706013A (ko) 1997-11-03
AU2281995A (en) 1996-04-26

Similar Documents

Publication Publication Date Title
DE69534874D1 (de) Immunotherapeutische stress-protein-peptidkomplexe gegen krebs
BR9303946A (pt) Macromolécula dendrítica e preparação da mesma
EP1001807A4 (de) Adoptive immunotherapie unter verwendung von hitze/stress protein-peptid komplexen zur vorbeugung/behandlung von krebs oder infektionskrankheiten
GR3034908T3 (en) Specific immune system modulation.
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
DK0771147T3 (da) Sammensætninger og fremgangsmåder til forhöjet tumorcelleimmunitet in vivo
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
HUT72187A (en) Recombinant method and host for manufacture of xylitol
TR24036A (tr) Soylu metal elektrolit coezeltilerinden paraziter elemanlarin ayiklanmasina mahsus usul
DE3860686D1 (de) Verschluss fuer einen einlassstutzen und verschlussaufbau.
CA2078773A1 (en) Gp75 as a tumor vaccine for melanoma
EP0202642A3 (de) Verfahren zur in vitro-Immunisierung von Humanmilzzellen gegen tumorassoziierte Antigene
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
IT8722414A0 (it) Immunoregolatore comprendente un derivato di estradiolo.
ES2089091T3 (es) Complejos que contienen acidos s(+)-fenilalcanoicos y acidos alfa-hidroalcanoicos.
IT8048077A0 (it) Complessi ortofosfati di cis-diammi noplatino ii e procedimento per trattare con essi tumori maligni in mammiferi
AU3347889A (en) Methods for identifying individuals genetically at risk for cancer
EP0183253A3 (en) Medicaments
Wyschogrod Comments on" Coming to the Messiah and Living in Christ"
Cooper Guest Editorial--Quaker Religious Thought, no. 65
Brown Some Implications for Peacemaking in Apocalyptic Times
Berk Response to Comments on" Coming to the Messiah and Living in Christ"
Roberts Front Matter--Quaker Religious Thought, no. 77
Jelly Summary Report of Replies to the Seminary Questionnaire
IT8620307A0 (it) Metodo di montaggio di mobili di malacca.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNI, US